Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the offering of 4,375,000 shares of common stock, alongside an equal number of Class E and Class F Common Warrants to purchase additional shares. The offering also includes up to 4,375,000 Pre-Funded Warrants to purchase common stock, with the potential for up to 13,125,000 shares of common stock underlying the warrants. This best efforts public offering aims to raise capital for the continued clinical development of Panbela's lead drug candidates, ivospemin and Flynpovi, as well as for general corporate purposes. The offering is set to terminate on February 15, 2024, unless completed sooner or terminated at the company's discretion. Panbela's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the offering of 4,375,000 shares of common stock, alongside an equal number of Class E and Class F Common Warrants to purchase additional shares. The offering also includes up to 4,375,000 Pre-Funded Warrants to purchase common stock, with the potential for up to 13,125,000 shares of common stock underlying the warrants. This best efforts public offering aims to raise capital for the continued clinical development of Panbela's lead drug candidates, ivospemin and Flynpovi, as well as for general corporate purposes. The offering is set to terminate on February 15, 2024, unless completed sooner or terminated at the company's discretion. Panbela's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.